구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)) Stephan Grupp MD PhD·CD22 6 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
PK/PD Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | All CRS (n=17, 89%) and neurotoxicity (n=4, 21%) events after initial infusion were grades 1-2. |
Toxicology Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Toxicology CRS | 89% |
Clinical Safety signal | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)) Stephan Grupp MD PhD·CD22 6 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
PK/PD Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | All CRS (n=17, 89%) and neurotoxicity (n=4, 21%) events after initial infusion were grades 1-2. |
Toxicology Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Toxicology CRS | 89% |
Clinical Safety signal | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교